Purpose We detail a unique case of a healthy 33-year-old suspected COVID-19 patient who presented with unilateral Central Retinal Vein Occlusion, possibly as a complication of COVID-19. Observations A 33-year-old healthy male was referred to the emergency department due to blurred vision in his left eye for the past month, accompanied by flashes of light without any accompanying neurological symptoms. The patient reported a three-week period of fatigue, dry cough, and shortness of breath ended about 2 weeks prior to the ocular symptoms. He was not tested for COVID-19 at the time of his respiratory complaints. The clinical examination and the ancillary tests confirmed the diagnosis of a left eye Central Retinal Vein Occlusion. During admission, a real-time reverse transcription-polymerase chain reaction (RT-PCR) for SARS-CoV-2 from a nasopharyngeal swab was performed and was found to be negative, however, an IgG/IgM Rapid Test (Inzek International Trading, the Netherlands) was performed and was found to be IgM negative and IgG Positive for SARS-CoV-2, confirming recovery from COVID-19. Conclusions and importance To the best of our knowledge this is the first report of CRVO in association with COVID-19. As the literature on human ocular manifestations of COVID-19 is still sparse, our case emphasizes the need for further investigation of ocular complication associated with this novel disease.

Staphylolysin provided long-lasting protection against several strains of S. aureus, evident by both its strong anti-bacterial activity and beneficial histopathological results of treatment.

DK-SRK/T overestimates IOL power in eyes with large AL, especially with concomitant steep pre-lasik keratometry. Among third-generation formulas, DK-Holladay 1 seems more accurate to use in postmyopic LASIK eyes.

Purpose: To compare results of two ophthalmic viscosurgical devices (OVDs) - Viscoat (a dispersive OVD, Alcon) and FR-Pro (a viscous-cohesive OVD, Rayner), in phacoemulsification surgery. Methods: A prospective randomized controlled study. Patients undergoing phacoemulsification were randomly assigned to receive one of the two OVDs. Exclusion criteria were age under 40, preoperative endothelial cell count (ECC) below 1,500 cells/mm2 and an eventful surgery. The primary outcome was change in ECC from baseline to postoperative month-one and month-three. Secondary outcomes were the difference between ECC at postoperative month-one and month-three, changes in IOP and occurrence of an IOP spike≥30 mmHg after surgery. Results: The study included 84 eyes - 43 in the Viscoat group and 41 in the FR-Pro group. Mean cell density loss at month-one and month-three was 17.0% and 19.2%, respectively, for the Viscoat group and 18.4% and 18.8%, respectively, for the FR-Pro group, with no statistically significant difference between the groups (p=0.772 and p=0.671, respectively). The mean ECC difference between the month-one and month-three visits was 50.5 cells/mm2 and was not statistically significant (p=0.285). One eye in each group had an IOP spike≥30 mmHg, both normalized by postoperative week-one. Conclusions: Viscoat and FR-Pro have comparable results following phacoemulsification surgery, suggesting that while FR-Pro is not a dispersive OVD, its endothelial cell protection may be comparable to one, perhaps due to the addition of sorbitol. Furthermore, a one-month follow-up of ECC seems sufficient in such trials.